Neumora Therapeutics, Inc. (NMRA): restructuring charge — Neumora discontinues navacaprant after Phase 3 MDD failures; cuts workforce 35%

Neumora Therapeutics, Inc.

Navacaprant failed primary endpoint in KOASTAL-2 (p=0.813) and KOASTAL-3 (p=0.480); development discontinued.
Company reducing workforce ~35%, expects ~$10M annualized savings, ~$2M restructuring costs in Q2 2026.
Cash and cash equivalents expected to fund operations into Q3 2027.
Pipeline focus shifts to NMRA-511 (Alzheimer's agitation), NMRA-898 (schizophrenia), NMRA-215 (obesity) with multiple milestones in H2 2026.
Third Amendment to loan agreement extends interest-only period; minimum liquidity covenant tied to milestones or market cap effective July 1, 2026.

item 1.01 item 2.03 item 2.05 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Neumora Therapeutics, Inc. amended Third Amendment to the Loan and Security Agreement with K2 HealthVentures LLC (effective 2026-06-10).

Action: amendment
Agreement: credit facility
Counterparty: K2 HealthVentures LLC
Effective: 2026-06-10

Exact text from the filing

On June 10, 2026, Neumora Therapeutics, Inc. (the “Company” or “Neumora”) as borrower, entered into a Third Amendment to the Loan and Security Agreement (the “Third Amendment”), with K2 HealthVentures LLC as a lender, and the lenders party thereto from time to time (collectively, “Lenders”, and each, a “Lender”), and K2 HealthVentures LLC, as administrative agent for Lenders.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Neumora Therapeutics, Inc. announced a restructuring with charges of approximately $2 million (approximately 35%).

Type: restructuring
Charge: approximately $2 million
Headcount: approximately 35%

Exact text from the filing

On June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately $2 million to be incurred in the second quarter of 2026.

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-270328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.